Published on : Jun 21, 2016
ALBANY, New York, June 21, 2016: The global market for intravenous iron drugs has been analyzed in a detailed market research report recently featured on ResearchMoz.us. The report is titled “Global Intravenous (IV) Iron Drugs Market Report: 2016 Edition.”
The 51-page document gives an expansive account of the past and present state of the market and an exclusive forecast summarizing the potential growth opportunities ahead of the market in the next few years in a precise, to-the-point manner. The projected impact of major growth opportunities, restraints, and trends on the overall future development of the market has also been included in the report.
The report presents an overview of the major elements of the market in a ground-up manner. It begins with an introduction of the importance of iron in the human body, the various modes of supplying iron to the body, the major applications of intravenous iron, such as in conditions such as nephrology and anemia. The several varieties of intravenous iron therapies available for the treatment of anemia are also analyzed in the report.
Iron is highly essential for the proper working of a number of bodily functions, such as the production of hemoglobin and thus the proper transportation of oxygen in the blood. The body cannot produce iron on its own and the only way to provide it is via the diet.
Click here to get more info with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=731843
As intravenous treatment, the way of delivering medications directly in veins, is one of the fastest way of delivering drugs and fluids to the body, it is highly preferred in several medical interventions compared to other modes of infusing drugs. The global intravenous iron drugs market is a prominent segment of the intravenous drug delivery industry and has witnessed substantial growth in the past few years.
Some of the major application areas of intravenous iron drugs market are gastroenterology, gynecology, surgeries, and oncology. Key varieties of iron molecules critical for the proper regulation and functioning of iron in the body include hepcidin, ferritin, hemoglobin, and transferrin.
The major factors driving the market include the rising number of dialysis cases across the globe, rising global population of geriatrics, increased healthcare expenditure worldwide, rising life expectancy, and increasing number of end state renal diseases (ESRD). Some of the noteworthy trends in the market include the development of new product varieties, the introduction of first generation drugs such as Dexeferrum (iron dextra) and InFed (iron dextran), and Feraccru. However, the market’s growth is projected to be limited to a certain extent in the next few years owing to the emergence of several alternate anemia management therapies.
The competitive landscape of global IV iron drugs market exhibits intense competition owing to the presence of several influential vendors. The report profiles some of these important vendors in the market, including Allergan plc, Galenica Pharmaceuticals, and AMAG Pharmaceuticals.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on [email protected]